GlassScriptPhysician profile
Laura E Finn
NPI 1770774549
$170,836.46
in general payments reported to CMS, 2019-2025
42 companies · $15K in 2025
The $15K reported for 2025 was more than what 84% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $25K · 2021: $25K · 2022: $31K · 2023: $38K · 2024: $25K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $66K · Travel and Lodging: $3,833 · Consulting Fee: $3,595 · Food and Beverage: $3,381 · Education: $274.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $66,380.00 |
| Travel and Lodging | $3,832.98 |
| Consulting Fee | $3,595.00 |
| Food and Beverage | $3,381.27 |
| Education | $273.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $56,675.20 | 2020-2025 | Brukinsa |
| E.R. Squibb & Sons, L.L.C. | $26,582.59 | 2022-2025 | Reblozyl, Opdivo |
| Celgene Corporation | $21,817.76 | 2019-2024 | Reblozyl |
| Lilly USA, LLC | $20,497.50 | 2022-2024 | Jaypirca |
| Jazz Pharmaceuticals INC. | $12,378.82 | 2019-2021 | |
| Beone Medicines USA, INC. | $9,131.42 | 2025 | Brukinsa |
| Genzyme Corporation | $4,154.16 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $2,919.55 | 2024-2025 | |
| Adc Therapeutics America, INC. | $2,896.07 | 2022-2023 | |
| Kite Pharma, INC. | $2,650.50 | 2020-2025 | Yescarta |
| Amgen INC. | $2,622.36 | 2019-2020 | |
| Janssen Biotech, INC. | $2,235.32 | 2020-2022 | |
| Epizyme, INC. | $2,025.00 | 2020 | |
| Daiichi Sankyo INC. | $869.44 | 2019-2025 | Datroway |
| Astellas Pharma US INC | $545.99 | 2019-2024 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $464.40 | 2021-2024 | Jakafi |
| Beigene, LTD. | $450.00 | 2020 | |
| Novartis Pharmaceuticals Corporation | $297.76 | 2019-2025 | |
| Abbvie INC. | $246.11 | 2019-2025 | |
| Octapharma USA, INC. | $215.80 | 2023 | Nuwiq |
| Genetix Biotherapeutics INC | $214.45 | 2023-2024 | |
| Aurobindo Pharma USA, INC. | $120.90 | 2019 | |
| Sobi, INC | $119.14 | 2023 | |
| Cti Biopharma Corp. | $111.76 | 2023 | Vonjo |
| Takeda Pharmaceuticals U.S.A., INC. | $103.31 | 2020 | |
| Merck Sharp & Dohme LLC | $88.55 | 2019 | |
| Janssen Scientific Affairs, LLC | $81.12 | 2022-2023 | Darzalex, Tecvayli |
| Pharmaessentia USA Corporation | $80.42 | 2022 | |
| Legend Biotech USA INC. | $65.66 | 2023-2024 | Carvykti |
| Karyopharm Therapeutics INC. | $48.55 | 2020 | |
| Genmab U.S., INC. | $27.34 | 2024 | Epkinly |
| Pharmacyclics LLC, An Abbvie Company | $25.82 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $21.71 | 2023 | Valchlor |
| Pfizer INC. | $20.53 | 2024 | |
| Sanofi-Aventis U.S. LLC | $17.00 | 2021 | |
| Terumo Bct, INC. | $14.45 | 2025 | Spectra Optia |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Finn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.